Minerva Neurosciences Earnings Call Transcripts
Fiscal Year 2026
-
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise as a monotherapy that improves both symptoms and functioning without typical antipsychotic side effects. The pivotal trial is underway, with top-line results expected in the second half of next year.
-
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise in improving both symptoms and daily functioning. The ongoing confirmatory phase III trial, supported by strong FDA engagement and $200 million in financing, aims to validate these results and enable U.S. launch.
-
The event detailed the clinical and regulatory progress of roluperidone for negative symptoms in schizophrenia, highlighting robust efficacy, low relapse rates, and a strategic phase III trial design. Experts emphasized the drug's unique mechanism and potential for broader indications, with strong investor and FDA support.